全文获取类型
收费全文 | 282篇 |
免费 | 8篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 7篇 |
妇产科学 | 9篇 |
基础医学 | 76篇 |
口腔科学 | 2篇 |
临床医学 | 15篇 |
内科学 | 43篇 |
皮肤病学 | 9篇 |
神经病学 | 24篇 |
特种医学 | 3篇 |
外科学 | 39篇 |
综合类 | 2篇 |
预防医学 | 36篇 |
眼科学 | 2篇 |
药学 | 12篇 |
肿瘤学 | 9篇 |
出版年
2022年 | 3篇 |
2018年 | 4篇 |
2015年 | 3篇 |
2014年 | 5篇 |
2013年 | 9篇 |
2012年 | 18篇 |
2011年 | 8篇 |
2010年 | 3篇 |
2009年 | 8篇 |
2008年 | 13篇 |
2007年 | 15篇 |
2006年 | 33篇 |
2005年 | 10篇 |
2004年 | 11篇 |
2003年 | 17篇 |
2002年 | 10篇 |
2001年 | 9篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 2篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 4篇 |
1989年 | 2篇 |
1987年 | 9篇 |
1986年 | 3篇 |
1985年 | 9篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1979年 | 3篇 |
1897年 | 1篇 |
1892年 | 2篇 |
1890年 | 1篇 |
1885年 | 2篇 |
1881年 | 1篇 |
1879年 | 5篇 |
1878年 | 1篇 |
1876年 | 1篇 |
1875年 | 3篇 |
1873年 | 1篇 |
1872年 | 2篇 |
1871年 | 1篇 |
1870年 | 1篇 |
1869年 | 2篇 |
1868年 | 1篇 |
1867年 | 4篇 |
排序方式: 共有291条查询结果,搜索用时 10 毫秒
91.
Ohne Zusammenfassung
Hierzu Taf. V. 相似文献
92.
Th. Langhans 《Virchows Archiv : an international journal of pathology》1868,42(3):382-404
Ohne ZusammenfassungHierzu Taf. VII–VIII. 相似文献
93.
Professor Theodor Langhans 《Virchows Archiv : an international journal of pathology》1911,206(3):419-437
Ohne ZusammenfassungHierzu eine Textfigur. 相似文献
94.
Th. Langhans 《Virchows Archiv : an international journal of pathology》1897,149(1):155-187
Ohne Zusammenfassung 相似文献
95.
96.
Dr. G. L. Langhans 《European journal of pediatrics》1925,39(2-3):344-348
Ohne Zusammenfassung 相似文献
97.
Luisa Klotz Sven Burgdorf Indra Dani Kaoru Saijo Juliane Flossdorf Stephanie Hucke Judith Alferink Nina Novak Marc Beyer Gunter Mayer Birgit Langhans Thomas Klockgether Ari Waisman Gerard Eberl Joachim Schultze Michael Famulok Waldemar Kolanus Christopher Glass Christian Kurts Percy A. Knolle 《The Journal of experimental medicine》2009,206(13):3159
98.
99.
Chang KC Tseng CD Wu MS Liang JT Tsai MS Cho YL Tseng YZ 《European journal of clinical investigation》2006,36(8):528-535
BACKGROUND: Formation of advanced glycation end-products (AGEs) on collagen within the arterial wall may be responsible for the development of diabetic vascular injury. This study focused on investigating the role of aminoguanidine (AG), an inhibitor of AGE formation, in the prevention of noninsulin-dependent diabetes mellitus (NIDDM)-derived arterial stiffening and cardiac hypertrophy in rats. MATERIALS AND METHODS: The NIDDM was induced in male Wistar rats, which were administered intraperitoneally with 180 mg kg(-1) nicotinamide (NA) 30 min before an intravenous injection of 50 mg kg(-1) streptozotocin (STZ). After induction of diabetes mellitus type 2, animals receiving daily peritoneal injections with 50 mg kg(-1) AG for 8 weeks were compared with the age-matched, untreated, diabetic controls. RESULTS: After exposure to AG, the STZ-NA diabetic rats had improved aortic distensibility, as evidenced by 18.8% reduction of aortic characteristic impedance (P < 0.05). Treatment of the experimental syndrome with AG also resulted in a significant increase in wave transit time (+23.7%, P < 0.05) and a decrease in wave reflection factor (-26.6%, P < 0.05), suggesting that AG may prevent the NIDDM-induced augmentation in systolic load of the left ventricle. Also, the glycation-derived modification on aortic collagen was found to be retarded by AG. The diminished ratio of left ventricular weight to body weight suggested that prevention of the diabetes-related cardiac hypertrophy by AG may correspond to the drug-induced decline in aortic stiffening. CONCLUSIONS: Long-term administration of AG to the STZ-NA diabetic rats imparts significant protection against the NIDDM-derived impairment in vascular dynamics, at least partly through inhibition of the AGE accumulation on collagen in the arterial wall. 相似文献
100.
Peters V Garbade SF Langhans CD Hoffmann GF Pollitt RJ Downing M Bonham JR 《Journal of inherited metabolic disease》2008,31(6):690-696
Summary A programme for proficiency testing of biochemical genetics laboratories undertaking urinary qualitative organic acid analysis
and its results for 50 samples examined for factors contributing to poor performance are described. Urine samples from patients
in whom inherited metabolic disorders have been confirmed as well as control urines were circulated to participants and the
results from 94 laboratories were evaluated. Laboratories showed variability both in terms of their individual performance
and on a disease-specific basis. In general, conditions including methylmalonic aciduria, propionic aciduria, isovaleric aciduria,
mevalonic aciduria, Canavan disease and 3-methylcrotonyl-CoA carboxylase were readily identified. Detection was poorer for
other diseases such as glutaric aciduria type II, glyceric aciduria and, in one sample, 3-methylcrotonyl-CoA carboxylase deficiency.
To identify the factors that allow some laboratories to perform well on a consistent basis while others perform badly, we
devised a questionnaire and compared the responses with the results for performance in the scheme. A trend towards better
performance could be demonstrated for those laboratories that regularly use internal quality control (QC) samples in their
sample preparation (p = 0.079) and those that participate in further external quality assurance (EQA) schemes (p = 0,040). Clinicians who depend upon these diagnostic services to identify patients with these defects and the laboratories
that provide them should be aware of the potential for missed diagnoses and the factors that may lead to improved performance.
Electronic supplementary material The online version of this article (doi: ) contains supplementary material, which is available to authorized users.
Competing interests: None declared 相似文献